Skip to main content
Browse by:
GROUP

Effective March 10, 2020, all Duke-sponsored events over 50 people have been cancelled, rescheduled, postponed or virtualized.
Please check with the event contact regarding event status. For more information, please see https://coronavirus.duke.edu/events

Modeling and testing in high-throughput cancer drug screenings

Event Image
Icon calendar
Thursday, February 13, 2020
Icon time
12:00 pm - 1:00 pm
Icon speaker
Wesley Tansey, postdoctoral research scientist at Columbia University Medical Center

High-throughput drug screens enable biologists to test hundreds of candidate drugs against thousands of cancer cell lines. The sensitivity of a cell line to a drug is driven by the molecular features of the tumor (e.g. gene mutations and expression). In this talk, I will consider two scientific goals at the forefront of cancer biology: (i) predicting drug response from molecular features, and (ii) discovering gene-drug associations that represent candidates for future drug development. I will present an end-to-end model of cancer drug response that combines hierarchical Bayesian modeling with deep neural networks to learn a flexible function from molecular features to drug response. The model achieves the first goal of state-of-the-art predictive performance, but the black box nature of deep learning makes the model difficult to interpret, presenting a barrier to the second goal of uncovering gene-drug associations. I will use this challenge as motivation for the development of a new method, the holdout randomization test (HRT), for conditional independence testing with black box predictive models. Applying the HRT to the deep probabilistic model of cancer drug response yields more biologically-plausible gene-drug associations than the current analysis technique in biology.

Contact: Ellen Currin